Search the Newsreel

What Does IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Indicate?

This article analyzes IDEXX Laboratories, Inc.'s stock price movements and valuation, utilizing a discounted cash flow (DCF) model to estimate its intrinsic value. It suggests the stock may be trading below its fair value, indicating potential for growth despite a recent price decline.

Nordex secures 525MW turbine order from Türkerler

Nordex Group has secured a contract from Türkerler Holding to supply and install wind turbines with a total capacity of approximately 525MW for a project in Türkiye. The agreement concerns the YEKA-5 R25 Sivas wind project and involves the delivery of 72 N175/6.X turbines …

IDEXX Laboratories Inc (IDXX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Projeções de Resultados: IDEXX Laboratories Inc (IDXX) — LPA e Crescimento de Receita

Royal Bank of Canada Decreases Position in IDEX Corporation $IEX

Royal Bank of Canada reduced its stake in IDEX Corporation by 6.9% in the first quarter of 2026, selling 6,645 shares and retaining 89,664 shares valued at $17 million. Despite this reduction, institutional investors collectively own 97.96% of IDEX. The company reported strong quarterly …

Pro-Dex Inc (PDEX) Earnings Forecast: Future EPS & Revenue Growth Estimates

DexCom Inc. Stock Sheds 4.9%, Underperforms Market

The article reports that DexCom Inc. (DXCM) stock experienced a 4.9% decline, leading to its underperformance in the market. The brief notice, sourced from Dow Jones, indicates a negative movement for the company's shares. Further details require a user to log in.

There May Be Underlying Issues With The Quality Of Standex International's (NYSE:SXI) Earnings

Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter.

Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates

Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary

Celldex Therapeutics, Inc. reported its financial results for the quarter ended 2026, with revenue of $22K and a diluted loss per share of ($0.94), resulting in a net loss of ($73.5M) due to ongoing investments in trials and manufacturing. The company highlighted clinical milestones, …

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Celldex reported its second-quarter 2026 financial results, highlighting ongoing Phase 3 studies for barzolvolimab in chronic spontaneous urticaria with topline data expected in Q3/Q4 2026, and actively enrolling patients for cold urticaria and symptomatic dermographism studies. The company also announced positive Phase 1 results …

Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million

Celldex reported a wider net loss of $

Standex International rated Hold despite growth in power, data centers, and defense sectors.

Standex International received a Hold rating due to its high valuation at a 31.3x forward P/E, significantly above the sector median. Despite expected mid-to-high single-digit sales growth by FY2027 driven by new products and strong demand in key sectors like power infrastructure, data centers, …

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M

Celldex Therapeutics, Inc. (CLDX) announced its Q2 revenue was $0.0M, as detailed in an earnings flash from MarketScreener. The company, a clinical-stage biotechnology firm, focuses on developing antibody-based therapeutics for inflammatory, allergic, autoimmune, and other diseases. Recent news also included adjustments to price targets …

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) reported a Q2 loss of $0.94 per share, which was better than the Zacks Consensus Estimate of a $1.04 loss, but missed revenue estimates significantly, posting only $0.02 million against an expectation of $0.73 million. Despite the revenue miss, the company's …

FedEx Freight's top execs combined for $16M in compensation before spinoff

FedEx Freight's top executives received a combined $16 million in compensation before the $8.8 billion revenue segment completed its separation from FedEx Corp. on June 1. This article, updated on August 6, 2026, details the financial aspects of the spin-off and the executive compensation …

D.A. Davidson Maintains IDEX Corp(IEX.US) With Hold Rating, Raises Target Price to $240

D.A. Davidson has reiterated a Hold rating on IDEX Corp (IEX.US) while increasing its price target to $240. This adjustment reflects the firm's updated valuation for the company.

IDEX Corp. stock underperforms Thursday when compared to competitors

IDEX Corp. (IEX) stock fell 1.38% on Thursday, closing at $233.71, underperforming the broader market. This marked the second consecutive day of losses for the company, as the S&P 500 Index (SPX) also declined by 0.18% and the Dow Jones Industrial Average (DJIA) fell …

Are You Looking for a Top Momentum Pick? Why Idex (IEX) is a Great Choice

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of …

Standex International About To Put More Money In Your Pocket (SXI)

Looking at the universe of stocks we cover at Dividend Channel, on 8/7/26, Standex International Corp. (Symbol: SXI) will trade ex-dividend, for its quarterly dividend of $0.34, payable on 8/21/26. As a percentage of SXI's recent stock price of $328.10, this dividend works out …

Medexus Pharmaceuticals Inc. Revenue Breakdown – TSX:MDP

Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Codexis Inc (CDXS), highlighting its current earnings forecast score of 8.00 and an average price target of $7.00. Based on ratings from 7 analysts, the stock has a "Buy" trend with a significant upside space. The company's …

Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M

Dexcom Inc (DXCM) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

How IDEXX’s Raised 2026 Earnings Outlook Will Impact IDEXX Laboratories (IDXX) Investors

IDEXX Labs Is Maintained at Neutral by UBS

UBS has maintained its "Neutral" rating on IDEXX Labs (IDXX) stock. This indicates that the analyst believes the stock will perform in line with the market. No specific financial data or price targets were provided in this brief announcement.

The 5 Most Interesting Analyst Questions From Standex’s Q2 Earnings Call

IDEX CORPORATION : ARGUS RESEARCH RAISES TARGET PRICE TO $260 FROM $250

Argus Research has increased its target price for IDEX Corporation (IEX.N) to $260 from $250. This update was reported by Reuters on August 6, 2026. The article itself is a brief news alert, providing no further details on the rationale behind the target price …

Dexterra Group (TSX:DXT) Stock Faces Margin Squeeze Despite Revenue Growth

DexCom Inc (DXCM) draws heavier trading as weekly gain hits 16.6%

The continuous glucose monitoring maker’s 12-week advance now stands at 37.7%, with trend and relative-strength readings still constructive.

DexCom Inc. stock underperforms Wednesday when compared to competitors

DexCom Inc. (DXCM) shares fell 4.92% on Wednesday to close at $82.66, marking its second consecutive day of losses. This underperformance occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index declined. The stock's movement was …

FedEx buys its longtime South San Francisco warehouse for $94 million

FedEx has acquired its long-standing warehouse in South San Francisco for $94 million from Sagard Real Estate. This transaction, reported by the San Francisco Business Times, was the largest industrial deal in the region during the last quarter. The article highlights the significance of …

IDEXX Laboratories 2026: Revenue $1.22B, EPS $4.27— 10-Q Summary

IDEXX Laboratories reported strong financial results for the quarter ended 2026, with revenue of $1.22 billion and diluted EPS of $4.27, both exceeding the prior year. The growth was driven by higher volumes and prices in core segments, particularly recurring diagnostics and reference lab …

Celldex Therapeutics earnings up next as Phase III data looms By Investing.com

Celldex Therapeutics is set to report its second-quarter earnings, with investors focusing on the timing of topline data from its pivotal Phase III EMBARQ-CSU studies, expected in September to October. Analysts project a loss of $1.06 per share on revenue of $803,000, and Wall …

Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com

Celldex Therapeutics stock reached a 52-week high of $40.30, showcasing significant investor confidence with an 86.85% increase over the past year. Despite this surge and a market capitalization of $3.16 billion, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, …